Moreover, in individuals with breast and/or ovarian cancer, the BRCA1/2 status serves as an important guide for surgical treatment planning as well as medical management (chemotherapy and targeted therapy with poly (ADP-ribose) polymerase inhibitors (PARPi). Here, BRCA1 is linked to ovarian carcinoma.